 | |
| Clinical data | |
|---|---|
| Other names | URB597; URB-597; KDS-4103; ORG-231295 |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.164.994 |
| Chemical and physical data | |
| Formula | C20H22N2O3 |
| Molar mass | 338.407 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
EX-597 (former developmental code namesURB-597,KDS-4103, andORG-231295) is afatty acid amide hydrolase inhibitor (FAAH inhibitor)[1] which is under development for the treatment ofsocial anxiety disorder (or social phobia) andpost-traumatic stress disorder (PTSD).[2]
It is a relativelyselective andirreversible inhibitor of theenzymefatty acid amide hydrolase (FAAH).[3][4] FAAH is the primary degradatory enzyme for theendocannabinoidanandamide and, as such, inhibition of FAAH leads to an accumulation ofanandamide in theCNS andperiphery where it activatescannabinoid receptors. EX-597 has been found to elevate anandamide levels and have activity againstneuropathic pain in amouse model.[5]
Preclinical studies have shown FAAH inhibitors to increasebrain-derived neurotrophic factor (BDNF) levels in thehippocampus andprefrontal cortex,[6] highlighting their potential inaddiction treatment as "enviromimetics".[7] Indeed, Chauvet et al. found that chronic EX-597 administration inrats "significantly reduces cocaine-seeking behaviour and cue- and stress-induced relapse".[8]
EX-597 was at one point being developed byKadmus Pharmaceuticals, Inc. forclinical trials inhumans.[9]